Induction Regimen With Avelumab/BCG Appears to be a Well-Tolerated Option for BCG-unresponsive NMIBC
Treatment with avelumab (Bavencio) and BCG appeared to be well tolerated in a population of patients with BCG-unresponsive non–muscle invasive bladder cancer (NMIBC), according to findings from the ...
CD4, CD8 and PD1 immunoexpression in oral premalignant lesions (PML) and oral squamous cell carcinoma (OSCC) and its association with malignant transformation. Background: Bacille Calmette-Guerin (BCG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results